• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Hyperglycemia
    23 Drugs classified under this therapeutic system

    All the Therapeutic System Drugs

    Filter by letter: ALL A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    partial basket chart

    Thiazolidinediones. Pioglitazone 15, 30, 45 mg.
    TABS.: 15 mg, 30 mg, 45
    mg x 28.
    Once dly with or w/o food. Initial treat.:
    15 mg or 30 mg once dly; may be
    increased up to 45 mg once dly. May
    be used in combination with insulin.
    See lit. Elderly: No dose adjustment is
    necessary. Renal impair.ent: No dose
    adjustment is necessary in pts. with
    impaired renal func. (CLcr > 4 ml/min) Not to be used in dialysed pts. Hepatic
    impair.ent: should not be used in pts.
    With hepatic impair.ent Paediatric: Not
    to be used in children and adolescents
    under 18 yrs of age.
    As second or third line treatment of type 2
    diabetes mellitus: as monotherapy: in
    adult patients (particularly overweight
    patients) inadequately controlled by diet
    and exercise for whom metformin is
    inappropriate because of
    contraindications or intolerance as dual
    oral therapy in combination with
    metformin, in adult patients (particularly
    overweight patients) with insufficient
    glycaemic control despite maximal
    tolerated dose of monotherapy with
    metformin; with a sulphonylurea, only in
    adult patients who show intolerance to
    metformin or for whom metformin is
    contraindicated, with insufficient
    glycaemic control despite maximal
    tolerated dose of monotherapy with a
    sulphonylurea. As triple oral therapy in
    combination with: metformin and a
    sulphonylurea, in adult patients
    (particularly overweight patients) with
    insufficient glycaemic control despite dual
    oral therapy.Pioglitazone is also indicated
    for combination with insulin in type 2
    diabetes mellitus adult patients with
    insufficient glycaemic control on insulin
    for whom metformin is inappropriate
    because of contraindications or
    intolerance.After initiation of therapy with
    pioglitazone, patients should be reviewed
    after 3 to 6 months to assess adequacy of
    response to treatment (e.g. reduction in
    HbA1c). In patients who fail to show an
    adequate response, pioglitazone should
    be discontinued. In light of potential risks
    with prolonged therapy, prescribers should
    confirm at subsequent routine reviews
    that the benefit of pioglitazone is
    C/I: Hypersens. to product; cardiac
    failure or history of cardiac failure (NYHA
    stages I to IV); hepatic impair.ent;
    diabetic ketoacidosis; current bladder
    cancer or a history of bladder cancer;
    uninvestigated macroscopic haematuria.

    partial basket chart

    Sulphonylurea. Glimepiride 1, 2, 3, 4 mg.
    TABS: 30x 1 mg, 2 mg, 3 mg, 4 mg.
    Initial: 1-2 mg 1 x dly with break. or
    main meal. Maint: 1-4 mg 1 x dly. Max:
    8 mg 1 x dly. Incr. by increments of no
    more than 2 mg at 1-2 wk. intervals.
    See lit.
    Type II diabetes mellitus.
    C/I: hypersens.; diabet. ketoacidos., with
    or without coma.

    Bydureon 2 mg
    Astra Zeneca
    partial basket chart
    Bydureon 2 mg

    Incretin Mimetic. Exenatide 2 mg.
    for susp. for inj. 3 x 4 single-dose kits
    recommen. dose is 2 mg once weekly,
    for self administ. by the pts.
    type 2 diab. mellitus in combin.with
    Metformin, Sulphonylurea, Metformin and
    sulphonylurea in adults who have not
    achieved adequate glycaemic control on
    maximally tolerated doses of these oral
    C/I: Hypersens.to the active subst. or to
    any of the excipients

    Competact Tablets
    not in the basket chart
    Multiple ingredients
    Competact Tablets

    Biguanide, Thiazolidinediones. Pioglitazone (as HCl) 15 mg, Metformin Hydrochloride 850 mg.
    F.C. TABS. 56. 1 tab twice dly. Dose titrat. with pioglitazone should be consid. Not
    recommend. for pts. under 18 yrs. old.
    2nd line tmt. of type 2 diab. mell. adult
    pts., particul. overweight pts., who are
    unable to achieve suffic. glyc. control at
    their maxim. tolerated dose of oral
    metformin alone. After initiat. of ther. w/
    pioglitazone, review. pts after 3- 6 mnths
    to assess adeq. response to tmt. (e.g.
    reduct. in HbA1c). In pts. who fail adeq.
    response, pioglitazone should be discount.
    In light of potent. risks w/prolong. ther.,
    confirm at subseq. routine reviews that the
    benefit of pioglitazone is maintained.
    C/I: Hypersens. ,Card. fail., hist. of card. fail.
    (NYHA stages I to IV). Current/ hist blad.
    cancer, Uninvestigated macroscop.
    haematur., Acute or chron. dis. which may
    cause tissue hypox. (E.G. card. or resp. fail.,
    recent MI, shock), hep. impair., acute
    alcohol intox., alcoholism, diab.
    ketoacidosis or diabetic precoma, ren. fail.,
    ren. dysfunc. (CrCl <60 ml/min),Acute
    cond. with the potent. to alter ren. func.
    (such as: dehydr., severe infec., shock,
    intravasc. administ. of iod. contrast ag.),

    Astra Zeneca
    partial basket chart

    SGLT2 Inhibitor. Dapagliflozin (propanediol monohydrate) 5 mg, 10 mg.
    F.C. TAB.: 7, 14, 28, 30, 90, 98.
    Monother., add-on comb. ther.: 10
    mg×1/d for monother., add-on comb.
    ther. with other glucose-low. med. prod.
    include. insulin. Pts. with severe hep.
    imair. init. recom. dose is 5 mg. If well
    tolerated, the dose may be incr. to 10
    Indic. In adults aged 18 yrs., older with
    type 2 diabetes mell. to improve
    glycaemic control as: Monother.: when
    diet and exercise alone do not provide
    adequate glycaemic control in pts. for
    whom use of metformin is considered
    inappropriate due to intolerance. Add-on
    comb. ther.: In comb. with other glucoselow.
    med. products includ. insulin, when these,
    together with diet and exercise, do not
    provide adequate glycaemic control.
    C/I: Hypersens.

    Glimepiride Teva
    partial basket chart
    Glimepiride Teva

    Sulphonylurea. Glimepiride 1 mg, 2 mg, 3 mg, 4 mg.
    SCORED TAB: 30 x 1, 2, 3 and 4 mg. Usual start. dose is 1-2 mg once dly administ. with breakfast. The dose may be incr. as needed. Max. dly dose: 8 mg.
    NIDDM (adult-onset diabetes, type II diabetes), when diet, reg. phys. exerc., and weight reduct. alone cannot maint. therap. suit. blood glucose levels.
    C/I: Hypersens. Hypersens. to of sulfonylurea / sulfonamides derivat.(includ. skin react. dyspnea, hypotens. anaphylaxis.). Type 1 diab., sev. or unstab. diab., ketosis or acidosis as a complicat.  of diabet., or diabetic coma.

    Other therapeutic systems under Diabetes